The Food and Drug Administration today authorized emergency use of the monoclonal antibody bebtelovimab to treat COVID-19 in outpatients at risk of progressing to severe disease or hospitalization. The Department of Health and Human Services yesterday announced plans to distribute at least 600,000 free treatment courses of the drug to states. The government has agreed to buy the treatment courses from Eli Lilly for delivery in February and March, with an option to purchase 500,000 additional doses in the future, the agency said.
 
“Early data suggests that this new product by Lilly has activity against both Omicron and the BA.2 Omicron subvariant,” HHS said. “Should the BA.2 subvariant grow in proportion in the U.S., this potential treatment may help ensure that we can continue to offer monoclonal antibody treatment that works against that strain of the virus.”
 
 

Related News Articles

Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration this week…
Headline
The Food and Drug Administration today announced it has revoked the emergency use authorizations for the Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody…
Headline
The Centers for Disease Control and Prevention last night endorsed Moderna’s COVID-19 vaccine for children aged 6-17, as its advisory committee…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today unanimously recommended Moderna’s COVID-19 vaccine for…
Blog
A recent article in the Washington Post “COVID bailout rescued some hospitals while enriching others” is wrong. The reality is that all of America’s hospitals…
Headline
More than 1 million prescriptions for the COVID-19 antiviral pills Lagevrio and Paxlovid were dispensed between late December 2021 and May 2022, but dispensing…